JP2018503679A5 - - Google Patents

Download PDF

Info

Publication number
JP2018503679A5
JP2018503679A5 JP2017545878A JP2017545878A JP2018503679A5 JP 2018503679 A5 JP2018503679 A5 JP 2018503679A5 JP 2017545878 A JP2017545878 A JP 2017545878A JP 2017545878 A JP2017545878 A JP 2017545878A JP 2018503679 A5 JP2018503679 A5 JP 2018503679A5
Authority
JP
Japan
Prior art keywords
protein
radiolabeled
based probe
group
radiolabeled protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017545878A
Other languages
English (en)
Japanese (ja)
Other versions
JP6701217B2 (ja
JP2018503679A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/062502 external-priority patent/WO2016086036A2/en
Publication of JP2018503679A publication Critical patent/JP2018503679A/ja
Publication of JP2018503679A5 publication Critical patent/JP2018503679A5/ja
Application granted granted Critical
Publication of JP6701217B2 publication Critical patent/JP6701217B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017545878A 2014-11-25 2015-11-24 生物学的製剤の18f−放射性標識方法および組成物 Active JP6701217B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084366P 2014-11-25 2014-11-25
US62/084,366 2014-11-25
PCT/US2015/062502 WO2016086036A2 (en) 2014-11-25 2015-11-24 Methods and compositions for 18f-radiolabeling of biologics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020081102A Division JP7027480B2 (ja) 2014-11-25 2020-05-01 生物学的製剤の18f-放射性標識方法および組成物

Publications (3)

Publication Number Publication Date
JP2018503679A JP2018503679A (ja) 2018-02-08
JP2018503679A5 true JP2018503679A5 (enExample) 2018-12-20
JP6701217B2 JP6701217B2 (ja) 2020-05-27

Family

ID=54834953

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017545878A Active JP6701217B2 (ja) 2014-11-25 2015-11-24 生物学的製剤の18f−放射性標識方法および組成物
JP2020081102A Active JP7027480B2 (ja) 2014-11-25 2020-05-01 生物学的製剤の18f-放射性標識方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020081102A Active JP7027480B2 (ja) 2014-11-25 2020-05-01 生物学的製剤の18f-放射性標識方法および組成物

Country Status (8)

Country Link
US (2) US11229713B2 (enExample)
EP (2) EP4218832A3 (enExample)
JP (2) JP6701217B2 (enExample)
CN (1) CN107207379B (enExample)
EA (1) EA034516B1 (enExample)
ES (1) ES2941895T3 (enExample)
MX (1) MX385081B (enExample)
WO (1) WO2016086036A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2812208T3 (es) * 2013-03-14 2021-03-16 Bristol Myers Squibb Co Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
WO2016086036A2 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Methods and compositions for 18f-radiolabeling of biologics
JP6622814B2 (ja) 2014-11-25 2019-12-18 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company イメージングのための新規pd−l1結合ポリペプチド
WO2017201111A1 (en) 2016-05-19 2017-11-23 Bristol-Myers Squibb Company Pet-imaging immunomodulators
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
CN109562195A (zh) 2016-06-01 2019-04-02 百时美施贵宝公司 用pd-l1结合多肽进行pet成像
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
WO2018111976A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
KR102568559B1 (ko) * 2016-12-14 2023-08-18 얀센 바이오테크 인코포레이티드 Cd8a-결합 섬유결합소 iii형 도메인
CN110997698B (zh) 2017-06-23 2023-12-26 百时美施贵宝公司 充当pd-1拮抗剂的免疫调节剂
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators
WO2019166622A1 (en) 2018-03-01 2019-09-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
EP3764878B1 (en) * 2018-03-13 2026-02-25 Trust Bio-sonics Inc. Composition and methods for sensitive molecular analysis
CN108680637A (zh) * 2018-05-15 2018-10-19 苏州大学 基于马来酰亚胺衍生物组合的非同位素双标记方法
CN109239758B (zh) * 2018-07-27 2022-08-12 国家海洋局南海环境监测中心(中国海监南海区检验鉴定中心) 一种生物样品中伽马能谱核素检测分析方法
CN109350751B (zh) * 2018-09-05 2021-08-31 南方医科大学南方医院 一种靶向egfr的多肽类pet显像剂及其制备方法和应用
CN114786682B (zh) 2019-10-14 2024-07-16 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
GB201915206D0 (en) 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer
CN114929728A (zh) 2020-01-06 2022-08-19 百时美施贵宝公司 免疫调节剂
EP4100064A1 (en) * 2020-02-07 2022-12-14 Novartis AG Targeted plasma protein degradation
JP2023515633A (ja) 2020-02-28 2023-04-13 ブリストル-マイヤーズ スクイブ カンパニー 放射性標識されたフィブロネクチンに基づく足場および抗体ならびにそのセラノスティクス的使用
KR20220161407A (ko) 2020-03-30 2022-12-06 브리스톨-마이어스 스큅 컴퍼니 면역조정제
CN111856546B (zh) * 2020-06-23 2022-07-29 中国辐射防护研究院 一种关于海洋生物灰中Cs-137放化分析的制样方法
JP2024517610A (ja) 2021-04-14 2024-04-23 アロ・バイオセラピューティクス・カンパニー Cd71に結合するフィブロネクチンiii型ドメイン
KR20240031947A (ko) 2021-04-14 2024-03-08 에이알오 바이오테라퓨틱스 컴패니 Fn3 도메인-시르나 접합체 및 이의 용도
GB202108605D0 (en) * 2021-06-16 2021-07-28 Ge Healthcare Uk Ltd Effect of water content
WO2023014999A1 (en) * 2021-08-06 2023-02-09 The Johns Hopkins University Aluminum fluoride radiosynthesis of [18f]dk222

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5328679A (en) 1988-04-01 1994-07-12 Immunomedics, Inc. Methods for technetium/rhenium labeling of proteins
US5128119A (en) 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5746996A (en) 1994-06-03 1998-05-05 Immunomedics, Inc. Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
IL113610A0 (en) 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5753206A (en) 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
AU717020B2 (en) 1996-05-03 2000-03-16 Immunomedics Inc. Targeted combination immunotherapy of cancer
ATE380038T1 (de) 1996-07-12 2007-12-15 Immunomedics Inc Radiometall-bindende peptide analoge
IL131016A (en) 1997-01-21 2004-12-15 Gen Hospital Corp Selection of proteins using RNA-protein blends
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
DE69837095T2 (de) 1997-09-03 2007-11-22 Immunomedics, Inc. Fluorierung von proteinen und peptiden für positronemissionstomographie
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
JP2003528632A (ja) 2000-03-31 2003-09-30 インスティティ・パスツール 血管内皮成長因子(vegf)−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法
CA2416219C (en) 2000-07-11 2016-10-11 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US7556925B2 (en) 2001-04-04 2009-07-07 University Of Rochester ανβ3 integrin-binding polypeptide monobodies and their use
KR20030033007A (ko) 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
BRPI0510909A2 (pt) 2004-05-19 2008-12-16 Medarex Inc composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EA016577B1 (ru) 2005-09-26 2012-06-29 Медарекс, Инк. Конъюгаты антитело-лекарство и их применение
BRPI0619331A2 (pt) 2005-10-26 2011-09-27 Medarex Inc método para fazer um composto para preparar um análogo de cbi cc-1065, método para preparar um análogo de cbi cc-1065 e composto
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
AU2007325838B2 (en) 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
EP2111237B1 (en) 2006-12-11 2015-03-18 BRACCO IMAGING S.p.A. Fibrin-binding peptides and conjugates thereof
TWI412367B (zh) 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
JP2010519310A (ja) 2007-02-21 2010-06-03 メダレックス インコーポレイテッド 単一のアミノ酸を有する化学リンカーおよびその複合体
US20090176654A1 (en) 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
EP2036576A1 (en) 2007-09-17 2009-03-18 Bayer Schering Pharma Aktiengesellschaft ED-B fibronectin as stratification marker for antitumor drugs
EP2215246B1 (en) 2007-10-31 2015-01-07 MedImmune, LLC Protein scaffolds
JP2011507529A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド M13ファージのpIXへの融合を介する代替の足場タンパク質融合ファージ提示
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
AU2008345424A1 (en) 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
EP2247615B1 (en) 2008-02-14 2014-07-30 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
CN102076713B (zh) 2008-05-02 2015-03-25 诺华股份有限公司 改进的基于纤连蛋白的结合分子及其用途
AR071874A1 (es) 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
MX2011004550A (es) 2008-10-31 2011-07-20 Centocor Ortho Biotech Inc Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos.
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之egfr/igfir結合分子
CN102596992B (zh) 2009-02-12 2015-09-09 詹森生物科技公司 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
US9217210B2 (en) 2009-03-24 2015-12-22 North Carolina State University Process of making composite inorganic/polymer nanofibers
WO2011020033A2 (en) 2009-08-13 2011-02-17 Massachusetts Institute Of Technology Engineered proteins including mutant fibronectin domains
US9139825B2 (en) 2009-10-30 2015-09-22 Novartis Ag Universal fibronectin type III bottom-side binding domain libraries
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
WO2011100700A2 (en) 2010-02-12 2011-08-18 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
KR20130056870A (ko) 2010-04-13 2013-05-30 메디뮨 엘엘씨 피브로넥틴 ⅲ형 도메인에 기초한 다량체 스캐폴드
HUE029622T2 (en) 2010-04-30 2017-03-28 Janssen Biotech Inc Stabilized fibronectin domain compositions, methods and uses
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
EP3091028A1 (en) 2010-05-26 2016-11-09 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
AU2011283646B2 (en) 2010-07-30 2015-07-09 Novartis Ag Fibronectin cradle molecules and libraries thereof
EP3415528B1 (en) 2011-04-13 2021-05-26 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
WO2013010573A1 (en) 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
RS58801B1 (sr) 2012-09-13 2019-07-31 Bristol Myers Squibb Co Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin
ES2972124T3 (es) 2012-12-03 2024-06-11 Curasight As Péptidos marcados con un radionúclido que emite positrones para obtención de imágenes de PET del uPAR humana
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
WO2014124017A1 (en) 2013-02-06 2014-08-14 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
CA2901231C (en) 2013-02-15 2020-06-23 Thomas Jefferson University Kit comprising lyophilized compositions for tumor imaging
US9433689B2 (en) 2013-03-12 2016-09-06 The Board Of Trustees Of The Leland Stanford Junio Probes and methods of imaging non-Hodgkins lymphoma
US10556024B2 (en) 2013-11-13 2020-02-11 Whitehead Institute For Biomedical Research 18F labeling of proteins using sortases
AU2015231170B2 (en) 2014-03-20 2019-10-03 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type III domains
SG11201607818WA (en) 2014-03-20 2016-10-28 Bristol Myers Squibb Co Stabilized fibronectin based scaffold molecules
WO2015190613A1 (en) 2014-06-09 2015-12-17 Takeda Pharmaceutical Company Limited Radiolabeled compounds
EP3177640B1 (en) 2014-08-08 2020-05-06 The Board of Trustees of the Leland Stanford Junior University High affinity pd-1 agents and methods of use
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
WO2016086036A2 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Methods and compositions for 18f-radiolabeling of biologics
JP6622814B2 (ja) 2014-11-25 2019-12-18 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company イメージングのための新規pd−l1結合ポリペプチド
WO2016162368A1 (en) 2015-04-07 2016-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Non-invasive imaging of tumor pd-l1 expression
US10766946B2 (en) 2015-09-23 2020-09-08 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type III domains
EP3353198B1 (en) 2015-09-23 2020-06-17 Bristol-Myers Squibb Company Glypican-3binding fibronectin based scafflold molecules
EP3368557B1 (en) 2015-10-30 2026-03-25 Affibody AB New polypeptide
CA3001264A1 (en) 2015-10-30 2017-05-04 Affibody Ab Pd-l1 binding polypeptide
DK3402537T3 (da) 2016-01-15 2021-03-29 Rigshospitalet Kvantitativ PET-afbildning af vævsfaktorekspression under anvendelse af 18-F mærket, aktiv positions-inhiberet faktor VII
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
CN109562195A (zh) 2016-06-01 2019-04-02 百时美施贵宝公司 用pd-l1结合多肽进行pet成像

Similar Documents

Publication Publication Date Title
Wang et al. A review on curability of cancers: more efforts for novel therapeutic options are needed
Cheng et al. Analytical measurement of PEGylated molecules
Duan et al. First-in-human study of the radioligand 68Ga-N188 targeting nectin-4 for PET/CT imaging of advanced urothelial carcinoma
JP2019525891A5 (enExample)
Mitran et al. Bispecific GRPR-antagonistic anti-PSMA/GRPR heterodimer for PET and SPECT diagnostic imaging of prostate cancer
JP6701217B2 (ja) 生物学的製剤の18f−放射性標識方法および組成物
Schottelius et al. In vivo targeting of CXCR4—new horizons
Zhang et al. Recent advancement of PD-L1 detection technologies and clinical applications in the era of precision cancer therapy
Lesniak et al. Evaluation of PSMA-targeted PAMAM dendrimer nanoparticles in a murine model of prostate cancer
AU2015353573A1 (en) Novel PD-L1 binding polypeptides for imaging
JP2018508213A5 (enExample)
Rinne et al. PET and SPECT imaging of the EGFR family (RTK class I) in oncology
Benfante et al. An overview of in vitro assays of 64Cu-, 68Ga-, 125I-, and 99mTc-labelled radiopharmaceuticals using radiometric counters in the era of radiotheranostics
ME02806B (me) Protutijela protiv csf-1r
Sun et al. Beyond small molecules: antibodies and peptides for fibroblast activation protein targeting radiopharmaceuticals
Oroujeni et al. Preclinical evaluation of [68Ga] Ga-DFO-ZEGFR: 2377: A promising affibody-based probe for noninvasive PET imaging of EGFR expression in tumors
Heesch et al. Development of radiotracers for breast cancer—the tumor microenvironment as an emerging target
Yook et al. Dual-receptor-targeted (DRT) radiation nanomedicine labeled with 177Lu is more potent for killing human breast cancer cells that coexpress HER2 and EGFR than single-receptor-targeted (SRT) radiation nanomedicines
Thakur et al. Dual-isotope SPECT/CT imaging of the tuberculosis subunit vaccine H56/CAF01: Induction of strong systemic and mucosal IgA and T-cell responses in mice upon subcutaneous prime and intrapulmonary boost immunization
Zhou et al. A novel near-infrared fluorescent probe TMTP1-PEG4-ICG for in vivo tumor imaging
Rinne et al. Benefit of later-time-point PET imaging of HER3 expression using optimized radiocobalt-labeled affibody molecules
Karimi et al. Advances in molecular imaging of VEGFRs: Innovations in imaging and therapeutics
Echavidre et al. Recent pre-clinical advancements in nuclear medicine: pioneering the path to a limitless future
Braun et al. Synthesis, radiolabeling, and in vitro and in vivo characterization of heterobivalent peptidic agents for bispecific EGFR and integrin αvβ3 targeting
Toan Novel molecular classification of breast Cancer with PET imaging